Abcam Founder Speaks Out Against Growing Exodus of British Life Science Companies
- Jonathan Milner Founded Biotech Group Abcam in 1998
- Milner Aims to Thwart US Takeover Bid and Lists Potential UK Listing
- Abcam Moved Share Listing to Nasdaq Tech Market in New York in 2020
The entrepreneur behind one of Britain’s most successful life science companies has vowed to bring it back to the London stock market.
Jonathan Milner, a leading UK breast cancer specialist who founded Cambridge-based biotech group Abcam in 1998, is determined to thwart a US takeover bid.
In 2020, the company shifted its share listing to the Nasdaq tech market in New York.
If Milner succeeds, it would demonstrate a significant show of support for UK life sciences and the London stock market.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
